J9154 Insurance Policy Changes

Breyanzi® (lisocabtagene maraleucel) (Revised)

This is a revised Humana Medicare Advantage prior authorization policy for Breyanzi (lisocabtagene maraleucel), a CAR-T cell therapy for relapsed/refractory B-cell lymphomas and leukemias. The policy was updated on February 19, 2026, and maintains strict approval criteria including documented prior therapy lines, disease refractoriness/relapse timing, age ≥18, concurrent lymphodepleting chemotherapy, and a lifetime maximum of one dose per member. Primary CNS lymphoma cases are excluded.